Summary
Definition
History and exam
Key diagnostic factors
- mass
- upper/lower gastrointestinal bleed
- rash
- purplish macular-papular lesions
- abnormal uterine bleeding
- increased abdominal girth
- history of HIV infection
- features of acute abdomen
- neuropathic pain
Other diagnostic factors
- weight loss
- fatigue
- anorexia
- abdominal bloating, discomfort, pain
- unilateral extremity swelling
Risk factors
- genetically inherited syndromes
- radiation
- human herpesvirus-8 (HHV-8) infection
- congenital disorders
- lymphedema
- history of exposure to chemical carcinogens
Diagnostic tests
1st tests to order
- CT scan of primary tumor
- MRI of primary tumor
- CT scan chest
- biopsy for histology
Tests to consider
- HIV test
- ultrasound of primary tumor
- chest x-ray
- positron emission tomography (PET) scan
- endoscopy
- complete blood count (CBC)
- blood urea nitrogen (BUN)
- creatinine
- liver function tests (LFTs)
- echocardiogram or multigated acquisition (MUGA) scan
- gene rearrangement testing
Treatment algorithm
extremity: stage I
extremity: stage II-III, resectable
extremity: stage II-III, unresectable
extremity: stage IV, single organ + limited tumor bulk or regional nodes
extremity: stage IV, disseminated metastases
retroperitoneal/intra-abdominal: resectable
retroperitoneal/intra-abdominal: unresectable or stage IV
gastrointestinal stromal tumors: resectable with minimal morbidity
gastrointestinal stromal tumors: resectable with significant morbidity
gastrointestinal stromal tumors: unresectable, progressive, or metastatic with imatinib-sensitive mutation
gastrointestinal stromal tumors: unresectable, progressive, or metastatic with imatinib-insensitive mutation
recurrence
Contributors
Authors
James S. Hu, MD, FACP
Associate Professor of Clinical Medicine
USC Norris Comprehensive Cancer Center
Los Angeles
CA
Disclosures
JSH declares that he has no competing interests.
Sant P. Chawla, MD, FRACP
Director
Sarcoma Oncology Center
Santa Monica
CA
Disclosures
SPC declares that he has no competing interests.
Acknowledgements
Dr James S. Hu and Dr Sant P. Chawla would like to gratefully acknowledge Dr Swati Sikaria, Dr Jonathan C. Trent, Dr Saira Hassan, and Dr David Thomas, previous contributors to this topic.
Disclosures
SS, JCT and SH each declare that they have no competing interests. DT has received research support from Pfizer, Amgen, and Novartis.
Peer reviewers
Alfio Ferlito, MD, DLO, DPath, FRCSEd
Director
Department of Surgical Sciences
Professor and Chairman
ENT Clinic
University of Udine
Udine
Italy
Disclosures
AF declares that he has no competing interests.
Adrienne Flanagan, MB BCh FRCPath PhD
Professor of Musculoskeletal Pathology
Institute of Orthopaedics and Musculoskeletal Science
University College London
Stanmore
UK
Disclosures
AF declares that she has no competing interests.
Robert Maki, MB, PhD
Medical Oncologist
Memorial Sloan-Kettering Cancer Center
New York
NY
Disclosures
RM declares that he has no competing interests.
Differentials
- Lipoma
- Gastrointestinal ulcer
- Lymphoma
More DifferentialsGuidelines
- NCCN clinical practice guidelines in oncology: gastrointestinal stromal tumors (GIST)
- NCCN clinical practice guidelines in oncology: soft tissue sarcoma
More Guidelines- Log in or subscribe to access all of BMJ Best Practice
Use of this content is subject to our disclaimer